Clinical Trial: A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part Sarcoma

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional



Official Title: A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

Brief Summary:

Background:

Sometimes the cancer advanced alveolar soft part sarcoma (ASPS) cannot be helped with surgery or other treatment. The drug atezolizumab unblocks the immune system. This allows immune cells to recognize and attack tumor cells. The drug could shrink cancer but could also have side effects. Researchers want to study if the drug will shrink a tumor in people with advanced ASPS.

Objective:

To test good and bad effects of the drug atezolizumab.

Eligibility:

People at least 6 years old with ASPS that cannot be cured with surgery

Design:

Participants will be screened with heart and pregnancy tests. Some may have scans or other tests.

At the study start, participants will have:

  • Medical history
  • Physical exam
  • Heart, blood, and pregnancy tests
  • Scan to measure tumor
  • Optional tumor sample taken

Each study cycle is 21 days.

In cycle 1:

  • On day 1, participants will have blood tests. They will get the study drug in a vein for about 1 hour. They will be observed for a few hours after.
  • On days 8 and 15, participants will have blood tests.

In o